{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"41.69","value":"-24.53"},{"groupId":"OG001","spread":"47.06","value":"-16.25"},{"groupId":"OG002","spread":"39.97","value":"-11.25"},{"groupId":"OG003","spread":"32.35","value":"-59.02"},{"groupId":"OG004","spread":"44.23","value":"-63.79"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"description":"Percentage change was calculated as the (\\[post-baseline value minus the baseline value\\] / \\[baseline value\\]) \\* 100.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with myelodysplastic syndromes (MDS) or multiple myeloma (MM) who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 50 milligrams (mg) once daily (QD) administered as a monotherapy for up to 6 months.","id":"OG000","title":"Zilurgisertib 50 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 100 mg QD administered as a monotherapy for up to 6 months.","id":"OG001","title":"Zilurgisertib 100 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 200 mg QD administered as a monotherapy for up to 6 months.","id":"OG002","title":"Zilurgisertib 200 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 400 mg QD administered as a monotherapy for up to 6 months.","id":"OG003","title":"Zilurgisertib 400 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 600 mg QD administered as a monotherapy for up to 6 months.","id":"OG004","title":"Zilurgisertib 600 mg QD"}],"paramType":"MEAN","populationDescription":"Pharmacodynamic (PD) Evaluable Population: all participants who received at least 1 dose of zilurgisertib and provided at least 1 plasma/serum sample (1 PD measurement)","reportingStatus":"POSTED","timeFrame":"from Cycle 1 Day 15 to Cycle 7 Day 1","title":"Percentage Change in Hepcidin From Cycle 1 Day 15 to Cycle 7 Day 1","type":"SECONDARY","unitOfMeasure":"percent change"}